GeoVax Labs, Inc. (GOVX)

Market Cap	3.99M
Revenue (ttm)	n/a
Net Income (ttm)	-27.78M
Shares Out	2.31M
EPS (ttm)	-14.51
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95,605
Open	1.750
Previous Close	1.750
Day's Range	1.600 - 1.800
52-Week Range	1.380 - 11.535
Beta	2.93
Analysts	Strong Buy
Price Target	120.00 (+6,796.55%)
Earnings Date	May 14, 2024

About GOVX

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company is developing GEO-CM0...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 17
• Stock Exchange: NASDAQ
• Ticker Symbol: GOVX

Analyst Forecast

According to one analyst, the rating for GOVX stock is "Strong Buy" and the 12-month stock price forecast is $120.0.

Price Target

$120.0

(6,796.55% upside)

Analyst Consensus: Strong Buy